## MRK: Merck & Co., Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.0% below STRENGTH zone (3.0-6.0%); PEG 1.11 fails VALUE criteria (<1.0); RSI 72 overbought. Stock is in no-man's land without clear edge. Caution: overbought RSI (72).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($104.43)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 1)

**1. Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference**
- Source: BioSpace | 20260105T133534 | Neutral | Relevance: 100%
- Merck announced that Robert M. Davis, chairman and CEO, and Dr. Dean Y. Li, executive vice president and president of Merck Research Laboratories, will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference. The event is scheduled for Monday, January 12, 2026, at 4:30 p.m. PST / 7:30 p.m. EST. A live audio webcast of the presentation will be available for investors, analysts, media, and the general public.

**2. Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference**
- Source: Business Wire | 20260105T114700 | Neutral | Relevance: 100%
- Merck announced that its Chairman and CEO, Robert M. Davis, and Dr. Dean Y. Li, President of Merck Research Laboratories, will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference. The event is scheduled for January 12, 2026, and will be accessible via a live audio webcast to investors, analysts, media, and the public. This participation underscores Merck's commitment to engaging with the financial and healthcare communities.

**3. Merck & Co., Inc. (NYSE:MRK) Receives Average Recommendation of "Hold" from Analysts**
- Source: MarketBeat | 20260104T090826 | Somewhat-Bullish | Relevance: 100%
- Analysts have given Merck & Co., Inc. (NYSE:MRK) an average "Hold" rating, based on coverage from seventeen firms with an average one-year price target of $110.13. Recent analyst actions include Wells Fargo upgrading Merck to "overweight" with a $125 target, while Berenberg downgraded to "hold" with a $90 target. The company also increased its quarterly dividend to $0.85, offering a roughly 3.2% yield.

**4. Merck & Co., Inc. $MRK Shares Sold by Spirepoint Private Client LLC**
- Source: MarketBeat | 20260106T125424 | Neutral | Relevance: 100%
- Spirepoint Private Client LLC significantly reduced its stake in Merck & Co., Inc. (MRK) by 85.5% in Q3, selling 64,872 shares to hold 10,994 shares valued at $923,000. Additionally, EVP David Michael Williams sold 8,614 shares in November, decreasing his holdings by nearly 26%. Despite these sales, Merck has raised its quarterly dividend to $0.85 per share and carries a consensus "Hold" rating from analysts with an average target price of $110.13.

**5. Robeco Institutional Asset Management B.V. Sells 157,285 Shares of Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20260106T120032 | Neutral | Relevance: 100%
- Robeco Institutional Asset Management B.V. reduced its stake in Merck & Co., Inc. by 5.0% in Q3, selling 157,285 shares. Following this, EVP David Michael Williams also sold 8,614 shares of the company's stock. Merck recently increased its quarterly dividend to $0.85 per share, with an annualized dividend of $3.40.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | BMO Capital | $130 | $82 | +59% |
| 2025-12-15 | B of A Securiti | $120 | $105 | +14% |
| 2025-12-12 | Morgan Stanley | $102 | $100 | +2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | BMO Capital | up | Outperform |
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.2% (-0.3%)
- Blackrock Inc.: 8.7% (-1.6%)
- State Street Corpora: 4.8% (-0.3%)
- Wellington Managemen: 3.0% (-2.0%)
- JPMORGAN CHASE & CO: 2.8% (+121.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +25%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.11 suggests fair value with growth premium. Quality metrics strong (ROE 40%, ROA 14%, margin 30%). Balance sheet: $6.8B free cash flow. Analyst sentiment positive (3 raises, avg +25%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $271.9B |
| Beta | 0.30 |
| 52W Range | $73.31 - $110.17 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.11 |
| Forward P/E | 13.2 |
| Current P/E | 12.1 |
| YoY Growth | -7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 2.0% (minimal 5-day change). Below STRENGTH zone by 1.0pp (needs >3.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 72, risk of mean reversion. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.00% (CS: 61) | Neutral |
| RSI_14 | 72.0 | Overbought |
| MACD Histogram | 0.20 | Bullish |
| vs SMA20 | 1.060x | Above |
| vs SMA50 | 1.122x | Above |
| vs SMA200 | 1.270x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $108.95
- **Stop Loss:** $104.43 (4.1% risk)
- **Target:** $113.47 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 292
- **Position Value:** $31,813.40
- **Portfolio %:** 31.81%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-03 (Est: $2.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.58 | +9.9% |
| 2025Q2 | $2.03 | $2.13 | +5.0% |
| 2025Q1 | $2.14 | $2.22 | +4.0% |
| 2024Q4 | $1.67 | $1.72 | +3.3% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*